IL309569A - Therapeutic compounds - Google Patents

Therapeutic compounds

Info

Publication number
IL309569A
IL309569A IL309569A IL30956923A IL309569A IL 309569 A IL309569 A IL 309569A IL 309569 A IL309569 A IL 309569A IL 30956923 A IL30956923 A IL 30956923A IL 309569 A IL309569 A IL 309569A
Authority
IL
Israel
Prior art keywords
therapeutic compounds
therapeutic
compounds
Prior art date
Application number
IL309569A
Other languages
English (en)
Hebrew (he)
Inventor
Ajit K Parhi
Yi Yuan
Yongzheng Zhang
Jesus Rosado
Pratik Datta
Original Assignee
Taxis Pharmaceuticals Inc
Ajit K Parhi
Yi Yuan
Yongzheng Zhang
Jesus Rosado
Pratik Datta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taxis Pharmaceuticals Inc, Ajit K Parhi, Yi Yuan, Yongzheng Zhang, Jesus Rosado, Pratik Datta filed Critical Taxis Pharmaceuticals Inc
Publication of IL309569A publication Critical patent/IL309569A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL309569A 2021-06-22 2022-06-21 Therapeutic compounds IL309569A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163213519P 2021-06-22 2021-06-22
PCT/US2022/034374 WO2022271723A1 (en) 2021-06-22 2022-06-21 Therapeutic compounds

Publications (1)

Publication Number Publication Date
IL309569A true IL309569A (en) 2024-02-01

Family

ID=84544904

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309569A IL309569A (en) 2021-06-22 2022-06-21 Therapeutic compounds

Country Status (10)

Country Link
US (1) US20240317749A1 (enExample)
EP (1) EP4359416A4 (enExample)
JP (1) JP2024524213A (enExample)
KR (1) KR20240067229A (enExample)
CN (1) CN118251394A (enExample)
AU (1) AU2022297426A1 (enExample)
CA (1) CA3225427A1 (enExample)
IL (1) IL309569A (enExample)
MX (1) MX2024000022A (enExample)
WO (1) WO2022271723A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117815240A (zh) * 2023-12-11 2024-04-05 兰州大学 一类具有二氨基吡咯并喹唑啉结构的化合物在防治奶牛乳腺炎致病菌中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436524T3 (es) * 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
BR112013008527A2 (pt) * 2010-12-17 2016-07-12 Nerviano Medical Sciences Srl derivados de pirazolo-quinazolina substituídos como inibidores de cinase
US12428423B2 (en) * 2017-04-01 2025-09-30 Shengke Pharmaceuticals (Jiangsu) Ltd. 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
US11077109B2 (en) * 2017-08-01 2021-08-03 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
KR102464677B1 (ko) * 2017-08-11 2022-11-10 셍커 파마슈티컬스 (지앙수) 엘티디. 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
WO2022040596A1 (en) * 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
EP4204093A1 (en) * 2020-08-27 2023-07-05 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors

Also Published As

Publication number Publication date
WO2022271723A1 (en) 2022-12-29
EP4359416A1 (en) 2024-05-01
AU2022297426A1 (en) 2024-02-01
MX2024000022A (es) 2024-03-15
JP2024524213A (ja) 2024-07-05
US20240317749A1 (en) 2024-09-26
CA3225427A1 (en) 2022-12-29
CN118251394A (zh) 2024-06-25
KR20240067229A (ko) 2024-05-16
EP4359416A4 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
DK4165024T3 (da) Cyclobutyldihydroquinolinsulfonamid-forbindelser
EP4149460C0 (en) THERAPEUTIC SOLID DOSAGE FORMS
EP4129997A4 (en) Octahydropyrazinodiazanaphthyridine dione compounds
EP4114183C0 (en) FUNGICIDAL COMPOSITIONS
IL310528A (en) Pyrazolopyridinone compounds
IL282330A (en) Therapeutic compounds
EP4149556C0 (en) PEG LIPIDOIDS COMPOUNDS
DK4320112T3 (da) Pyridinylsubstituerede oxoisoindolinforbindelser
IL291486A (en) Therapeutic conjugates
EP3735463A4 (en) Cytotoxicity-inducing therapeutic agent
EP4143199C0 (en) NUCLEOTIDE PROMEDICINAL COMPOUNDS
IL292502A (en) Therapeutic methods using vadadustat
EP4362298A4 (en) UNIT
JP1708791S (ja) マッサージ器
EP4225129A4 (en) OCT GUIDED THERAPY
EP4361468A4 (en) SYSTEM
EP4362296A4 (en) UNIT
EP4090369A4 (en) PERICYTE-SPARKING THERAPY
IL289338A (en) Therapeutic interactions of leucomethylthioninium
EP4434969A4 (en) ANTI-SARS-CoV-2 MEDICATION
PT4038149T (pt) Compostos anti-incrustação
EP4083213A4 (en) Cancer gene therapy drug
IL313590A (en) Compounds
EP4359416A4 (en) THERAPEUTIC COMPOUNDS
EP4392459A4 (en) SINGLE-DOMAIN THERAPEUTIC ANTIBODY